Our lead product candidate is ataluren for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. Following is a list of ongoing ataluren clinical trials in patients with nonsense mutation genetic disorders. Read the ataluren overview to learn more about ataluren.

DMD-icon.pngAtaluren for nmDMD: Confirmatory Phase 3 clinical trial complete

CF-icon.pngAtaluren for nmCF: Phase 3 trial complete; Confirmatory Phase 3 clinical trial initiated

Additional information about ataluren clinical trials can be found at Clinicaltrials.gov or by contacting Patient and Professional Advocacy at (866) 282-5873, (908) 912-9256 or PatientInfo@ptcbio.com

You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue